Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Regulatory Approval

Supernus Pharmaceuticals Shares Rise 6% in 5 Days Since Securing FDA Orphan Drug Exclusivity

Supernus Pharmaceuticals Secures 7-Year FDA Orphan Drug Exclusivity for ONAPGO

+6.65% in 5 days $41.21 when we broke this story → $43.95 at 9:32 AM ET, 29 Oct 2026

Supernus Pharmaceuticals has obtained seven years of market exclusivity from the FDA for its Parkinson’s disease treatment, ONAPGO. The company also initiated a supplemental New Drug Application for a second manufacturing supplier to mitigate future supply chain risks.

Science, tubes, test, scientific. Stock photo illustrating Supernus Pharmaceuticals' regulatory approval story.
SUPERNUS PHARMACEUTICALS, INC. · Healthcare · Photo: PublicCo / Pixabay

Key highlights

  • FDA grants seven years of orphan-drug exclusive approval for ONAPGO (apomorphine HCl)
  • Market exclusivity period is retroactive to the initial approval date of February 3, 2025
  • Supplemental New Drug Application submitted for a secondary manufacturing supplier
  • Potential FDA approval for the second supplier is anticipated by mid-year 2027
  • ONAPGO is the first subcutaneous apomorphine infusion device for advanced Parkinson’s motor fluctuations

What Approval Was Received?

The U.S. Food and Drug Administration (FDA) has officially recognized seven years of orphan-drug exclusive approval for ONAPGO (apomorphine HCl). This regulatory milestone applies to the treatment of motor fluctuations in adult patients diagnosed with advanced Parkinson’s disease. The exclusivity period is valid through early 2032, as it was backdated to the medication's initial approval on February 3, 2025. The designation is part of the FDA's program to support the development of therapies for conditions affecting fewer than 200,000 individuals in the United States annually.

SUPERNUS PHARMACEUTICALS, INC. share price · last month
Line chart of SUPERNUS PHARMACEUTICALS, INC.'s share price over the last month, from $33.87 on 19 Oct → $28.83 on 16 Nov; our story on 22 Oct at $41.21.

Down 30.0% since our story on 22 Oct: $41.21 when we broke it → $28.83 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$33.87
20 Oct$34.77
21 Oct$34.79
22 Oct$35.33
23 Oct$34.47
26 Oct$34.56
27 Oct$34.72
28 Oct$34.77
29 Oct$35.25
30 Oct$35.37
2 Nov$36.28
3 Nov$28.15
4 Nov$28.21
5 Nov$26.74
6 Nov$26.16
9 Nov$27.62
10 Nov$28.75
11 Nov$29.45
12 Nov$29.20
13 Nov$29.72
16 Nov$28.83

Why This Approval Matters

Obtaining orphan-drug exclusivity provides a significant competitive moat by preventing the FDA from approving the same drug for the same indication for seven years. This protection is critical for Supernus as it scales ONAPGO, which remains the only subcutaneous apomorphine infusion device on the market. By securing this status, the company protects its intellectual property and market share against generic entries during the primary growth phase of the product. This development follows the company's successful effort in 2026 to clear a supply backlog of over 700 patients.

Path to Market

Beyond the exclusivity win, Supernus is actively diversifying its production capabilities to prevent future supply disruptions. The company has filed a supplemental New Drug Application (sNDA) for a second supplier, aiming for regulatory clearance by mid-2027. This move is designed to ensure an uninterrupted drug supply for the advanced Parkinson’s community. The expansion of the supply chain coincides with the company’s broader strategic shifts, including a pending merger of equals with Indivior Pharmaceuticals, which is scheduled to close on November 2, 2026.

Business Overview

Supernus Pharmaceuticals is a biopharmaceutical firm specializing in central nervous system (CNS) disorders. Its commercial portfolio includes treatments for ADHD, epilepsy, migraine, and Parkinson’s disease, featuring brands like Qelbree and Gocovri. For the full year 2026, management raised total revenue guidance to a range between $860 million and $890 million. The company maintains a strong focus on neuroscience, with an R&D pipeline targeting chronic sialorrhea and cervical dystonia. The upcoming third-quarter financial results are scheduled for release on October 29, 2026.

Earlier announcements by SUPERNUS PHARMACEUTICALS, INC.
DateAnnouncementAmount
21 Oct 2026Supplemental New Drug Application (sNDA) submitted to the FDA for a second manufacturing supplier for ONAPGOSource: ir.supernus.com–
21 Oct 2026FDA recognized 7 years of orphan-drug market exclusivity for ONAPGO (apomorphine HCl)Source: ir.supernus.com–
04 Feb 2025FDA approval of ONAPGO (apomorphine hydrochloride) infusion device for Parkinson's diseaseSource: ir.supernus.com–
27 Jan 2025FDA approval of expanded label update for Qelbree (viloxazine) adding pharmacodynamic and lactation dataSource: ir.supernus.com–

Management commentary

“Securing orphan-drug exclusivity marks an important milestone for individuals and families navigating Parkinson's disease. This designation validates the urgent need for targeted therapies and helps safeguard continued innovation in a long-underserved community.”

Jack Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals

“In addition to resolving the supply issue from earlier this year, submitting our sNDA further reinforces our ongoing commitment to providing novel treatments for patients with Parkinson's disease, backed by our unwavering focus on ensuring an uninterrupted drug supply for every patient in need.”

Jack Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals
SUPERNUS PHARMACEUTICALS, INC. · financial snapshot
Share price$41.21
Market cap$2.4B
Revenue (annual)$719M
1-month price change-3.67%
SectorHealthcareDrug Manufacturers - Specialty & Generic

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Supernus Pharmaceuticals, Inc. announcing FDA orphan-drug exclusivity recognition and a supplemental New Drug Application.

Read the filing ↗

Track SUPERNUS PHARMACEUTICALS, INC. live

Get the next SUPERNUS PHARMACEUTICALS, INC. SEC filing seconds after it lands.

More in Approvals

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.